Therapeutic advantage of combinatorial CAR T cell and chemo-therapies

Pharmacological Reviews, Год журнала: 2024, Номер 77(1), С. 100011 - 100011

Опубликована: Окт. 7, 2024

Chimeric antigen receptor (CAR) T cell therapies have transformed outcomes for many patients with hematological malignancies. However, some do not respond to CAR treatment, and adapting cells solid brain tumors has been met challenges including a hostile tumor microenvironment poor persistence. Thus, it is unlikely that therapy alone will be sufficient consistent, complete clearance across cancer patients. Combinatorial of chemotherapeutics are promising approach overcoming this as could augment improved anti-tumor activity or work in tandem clear tumors. Herein, we review efforts towards achieving successful chemical drug combination therapies. We focus on approved these more easily translated the clinic, but also non-approved screens designed reveal new combinations. Together, highlights promise chemotherapy combinations specific how combinatorial overcomes faced by either monotherapy supports potential therapeutic strategy improve Significance Statement Improving currently available products via drastically expand types cancers number benefit from when neither achieve clearance. provide thorough current studying perspectives optimal ways identify effective moving forward.

Язык: Английский

Machine learning identifies immune-based biomarkers that predict efficacy of anti-angiogenesis-based therapies in advanced lung cancer

International Immunopharmacology, Год журнала: 2024, Номер 143, С. 113588 - 113588

Опубликована: Ноя. 17, 2024

Язык: Английский